BridgeBio rises after late-stage muscular dystrophy trial success

[Double exposure microscope Young woman scientific using equipment for research. Genetic research and Biotech science Concept. Human Biology and pharmaceutical technology]
jittawit.21/iStock via Getty Images

BridgeBio Pharma (NASDAQ:BBIO [https://seekingalpha.com/symbol/BBIO]) shares rose after it announced positive results from its late-stage study of BBP-418 on patients with limb-girdle muscular dystrophy type 2I/R9.

The study successfully met all its main and secondary goals, showing a safety profile that aligns with previous research conducted by the company.

The stock is up 18.6% so far today.

The trial showed a significant increase in glycosylated αDG levels, which rose by 1.8 times from the starting point after three months. This improvement was maintained after twelve months for those receiving BBP-418 compared to those on a placebo.

The company said [https://seekingalpha.com/pr/20279851-bridgebio-reports-positive-phase-3-results-for-small-molecule-bbpminus-418-in-lgmd2i-r9]that in the trial, patients treated with BBP-418 experienced an average reduction of 82% in serum CK levels, a common indicator of muscle damage, which was statistically significant when compared to the placebo group after twelve months.

MORE ON BRIDGEBIO PHARMA

* BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 Transcript [https://seekingalpha.com/article/4833651-bridgebio-pharma-inc-bbio-discusses-positive-fortify-phase-iii-interim-results-in-limb-girdle]
* BridgeBio Pharma, Inc. (BBIO) Discusses Positive FORTIFY Phase III Interim Results in Limb-Girdle Muscular Dystrophy Type 2I/R9 - Slideshow [https://seekingalpha.com/article/4833655-bridgebio-pharma-inc-bbio-discusses-positive-fortify-phase-iii-interim-results-in-limb-girdle]
* BridgeBio Pharma, Inc. (BBIO) Presents at HFSA 2025 - Slideshow [https://seekingalpha.com/article/4827074-bridgebio-pharma-inc-bbio-presents-at-hfsa-2025-slideshow]
* SA Asks: What's the most attractive biotech stock right now? [https://seekingalpha.com/news/4503473-sa-asks-whats-the-most-attractive-biotech-stock-right-now]
* Pfizer, Alnylam earn BridgeBio ire over sales tactics for amyloidosis drugs: Bloomberg [https://seekingalpha.com/news/4494396-pfizer-alnylam-earn-bridgebio-ire-amyloidosis-drugs]